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Anaesthesia for a patient with beta thalassaemia major
T  Kallenbacha*
aDepartment of Anaesthesia, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
*Email: kalletf@yahoo.com
While beta thalassaemia is not a common disorder with an estimated 100 000 severely affected individuals worldwide, improved 
survival rates and increased global migration means an increased frequency of such patients being seen for various surgeries. 
The different aspects of this disorder have wide-ranging implications for anaesthesia. Thus, for safe anaesthetic care, the anaes-
thetist needs to have a good understanding of beta thalassaemia. Presented here is a case report of a 32-year-old gentleman 
with beta thalassaemia major presenting for elective laparoscopic cholecystectomy and splenectomy, followed by a discussion 
of the literature.
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Case report
In August 2014 Mr C, known to have beta thalassaemia major, 
presented for elective laparoscopic cholecystectomy and 
splenectomy. He had an eight-month history of gallstone-related 
symptoms progressing to two attacks of cholecystitis, worsening 
anaemia and jaundice.
Further questioning about his family history revealed that both 
his parents and three of his four siblings have beta thalassaemia 
minor. Mr C was diagnosed with beta thalassaemia major at 
around four months of age, after being noted with pallor by a 
family physician. He has required lifelong regular blood 
transfusions, receiving four units of washed red blood cell units 
every three weeks. He was also on lifelong iron chelation therapy, 
desferrioxamine and deferiprone. He had no cardiac or 
respiratory complications, and no history of endocrine or renal 
aberration attributable to iron overload. Prior to December 2013, 
he had no symptoms of liver dysfunction. A MRI done in 
December 2013 showed a normal heart, but moderate iron 
deposition in the liver. He had only one known adverse reaction 
to blood transfusion, and had no history of blood-borne 
infections and nothing else of note on history.
Mr C was thin and of short stature (weight 49  kg and height 
153  cm), likely due to growth insufficiency from the disorder 
itself. No other skeletal abnormalities were evident. On general 
examination, he had pallor and jaundice. His cardiac assessment 
revealed a hyperdynamic circulation with elevated heart rate, 
but no other abnormalities. His respiratory examination was 
unremarkable. His abdominal examination revealed 
hepatomegaly and splenomegaly. Airway assessment showed 
no facial deformities, with Mallampatti grade 2 and normal range 
of movements at cervical spine and temporomandibular joints.
Preoperative blood investigations showed an anaemia with a 
haemoglobin of 10.1  g/dl, and elevated AST and ALT. Chest 
radiography, electrocardiography and lung function tests did 
not yield additional information. He had already been vaccinated 
in anticipation of the splenectomy.
In theatre, consent was checked, standard ASA monitors were 
placed, and a 16-G intravenous cannula was inserted. Elective 
sequence induction was performed with fentanyl, propofol and 
rocuronium. Intubation was achieved easily. Anaesthesia was 
maintained with a balanced mixture of oxygen, air and isoflurane. 
In preparation for the possibility of significant haemorrhage, a 
second 16-G intravenous line and arterial line were inserted. 
Aseptic technique was adhered to, and antibiotic prophylaxis 
administered. Pressure points were protected, and temperature 
monitoring and management instituted. The first arterial blood 
gas sample prior to surgery starting was within normal limits, 
except for a low haemoglobin of 7.6 g/dl. Blood was ordered to 
theatre; however, incorrectly only normal red packed cell units 
were received. In discussion with the blood bank and the 
patient’s haematologist, it was decided to utilise these units. 
Graduated compression stockings were placed on the patient’s 
legs, he was cleaned and draped, and surgery commenced. 
Ventilation was adjusted during peritoneal insufflation to keep 
the ETC02 within normal limits, and airway pressures were 
monitored. Vitals were consistently stable, and on serial arterial 
blood gas samples the haemoglobin remained above 7.5  g/dl. 
Due to the risk of alloimmunisation, blood transfusion of one 
unit was only initiated at the end of the procedure, titrated to 
observed blood loss. Analgesia was multimodal, including 
intravenous opioids and local blocks done under direct vision by 
the surgeon. At the end of the procedure of four hours’ duration, 
neuromuscular blockade was reversed after checking the train-
of-four count. The patient was successfully extubated, and 
transferred to the high-dependency unit awake and pain free. 
Postoperatively, he was placed on prophylactic low molecular 
weight heparin with early mobilisation. He received his standard 




Haemoglobin contains two alpha, and two non-alpha, globin 
chains attached to four iron-containing heme complexes.1 Beta 
thalassaemia is a defect of the beta globin chains of the 
haemoglobin A molecule. The clinical presentation typically 
manifests at approximately four to six months of age, as during 
this time period haemoglobin F falls significantly to be replaced 
by haemoglobin A.2 This genetic disorder is transmitted by 
autosomal recessive inheritance.3 A defect in one beta globin 
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allele will result in beta thalassaemia minor. This is effectively a 
carrier state, and individuals are usually asymptomatic or present 
with anaemia. Defects in both alleles result in beta thalassaemia 
major, which results in a severe clinical picture requiring lifelong 
blood transfusions. A more moderate phenotype presenting 
with less blood transfusion dependence is called beta 
thalassaemia intermedia.1 The cause behind this differing 
severity of disease from the same genotype is unknown. 
However, the type of mutation and gene interactions are thought 
to play key roles.4
Epidemiology
According to a WHO review in 2008, the disorder is most 
prevalent in the Asian and Mediterranean regions.5 Theories to 
explain the higher numbers in these areas include protection 
against malaria and consanguinity.6 Due to global migration of 
people, beta thalassaemia is being seen more frequently in other 
countries of the world.6 About 1.5% of the world’s population are 
carriers for beta thalassaemia, with an estimated 100 000 
transfusion-dependent individuals living worldwide.5,6
Presentation and management
Due to this genetic abnormality, an excess of alpha chains is 
produced in the haemoglobin molecule. This creates an unstable 
profile, with precipitation of the alpha globins and resultant 
haemolysis of the red blood cell. As a result, there is increased 
but ineffective erythropoiesis.4 This leads to multiple systemic 
manifestations as outlined in Table 1.
The cornerstone of treatment is blood transfusions.7 Many 
specialised centres have 2–4-weekly transfusion programmes. 
Blood used is leucocyte-deplete with extended antibody typing 
that has been washed to reduce the risk of alloimunisation.2,8 
Patients who receive no or minimal blood transfusion in their 
lifetime generally only survive to the first/second decade of life.6 
However, this essential form of treatment comes with its own 
detrimental effects, including: worsening of iron overload; 
potential for adverse blood transfusion reactions; potential for 
transmission of blood-borne infections.2 Iron overload is a 
significant complication, and without treatment results in 
mortality in the second/third decade of life.3 Iron overload is due 
to chronic haemolysis, compensatory increased iron absorption 
from the gut, and frequent blood transfusions.4 The adverse 
organ effects of iron overload are summarised in Table 2.
Iron overload is countered by iron chelation therapy with the 
current frequently used drugs being desferrioxamine, 
deferiprone and deferisarox. These do have potential side effects 
Table 1: Systemic manifestations of the beta thalassaemia disorder1,3,6,9,10,16
Organ system Defects Pathophysiological mechanisms
Cardiac Cardiomegaly, dilated cardiomyopathy, congestive cardiac 
failure
High output state due to chronic anaemia, and hyper-
volemia from plasma expansion due to shunting of blood 
through the expanded marrowElectrophysiological abnormalities including repolarisation 
irregularities with increased risk of Torsade de Pointes, and 
ventricular tachycardia
Respiratory Restrictive lung disease Thoracic cage and spinal deformities
Muscle Decreased muscle development and weight gain leading to 
growth retardation and small stature
Increased metabolic demand
Decreased supply due to anaemia, chronic infections and 
frequent hospitalisations
Skeletal Craniofacial deformities (frontoparietal bossing, prominent zy-
gomatic bones, nasal bridge depression, maxillary prominence, 
dental abnormalities)
Expansion of ineffective extramedullary erythroid tissue
Compression of neural structures (spinal cord, optic nerve in 
optic canal)
Middle-ear occlusion with conductive hearing loss
Osteopenia leading to pathological fractures
Haematology Severe hypochromic microcytic anaemia Abnormal erythrocyte membranes leading to chronic 
haemolysis and sequestration by worsening splenomegaly
Haemodilution coagulopathy Large-volume blood transfusions
Hypercoagulable state leading to increased risk of thrombosis 
(arterial thrombosis predominant in beta thalassaemia major 
and venous thrombosis in beta thalassaemia intermedia)
Reduced nitric oxide as haemolysis increases the amount 
of free haemoglobin and arginine, which leads to increased 
nitric oxide scavenging and decreased bioavailability 
respectively
Erythrocyte membrane aberrations
Platelet and endothelial activation due to free haemoglobin
Low levels of antithrombin III, protein C and S
Vascular Vasculopathy including pulmonary hypertension and silent 
cerebral infarctions
Reduced nitric oxide carriage
Ischaemia-reperfusion injury
Endothelial activation




Risk of transmission of blood-borne infections Frequent blood transfusions
Iron overload
Splenectomy
Hepatic Increased incidence of gallstones Chronic haemolysis
Neurology Higher incidence of cognitive defects and impairment of neu-
ropsychological tests
Chronicity of disease with emotional, psychosocial and 
financial burdens
Varying limitations on quality of lifeIncreased incidence of depressive symptoms
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such as: sensorineural deafness, visual disturbances, vertebral 
dysplasia, growth retardation (desferrioxamine); agranulocytosis 
(deferiprone); transient deterioration in renal function, skin 
rashes, and gastrointestinal upset (desferasirox).3 Splenectomy 
has been shown to be effective in reducing transfusion 
requirements and improving morbidity.2,4 However, a 
splenectomy has its own host of complications, including 
increased risk of postoperative infections and thrombotic 
events.9 More novel treatment modalities include: stem cell 
transplantation; foetal haemoglobin inducers; gene therapy.2
Anaesthesia
The cardiovascular system should be carefully evaluated with 
particular attention to a history of poor exercise tolerance and 
dyspnoea.9 Preoperative evaluation will guide investigations 
such as electrocardiogram, echocardiography and cardiac 
catheterisation.2,10 If cardiac involvement is suspected, caution is 
warranted with cardiac suppressant agents intraoperatively and 
with the use of neuroaxial techniques to avoid depression of 
high cardiac output state.11 Depending on the operation, close 
haemodynamic monitoring should be considered with 
modalities such as an arterial line, minimally invasive cardiac 
output monitors, and transoesophageal echocardiography.10
Patients may present with asymptomatic restrictive lung disease, 
although occasionally an obstructive respiratory picture may be 
seen.12 Lung function tests are useful for diagnosis of this 
condition, and for quantification of severity. It must also be 
borne in mind that these patients may present with pulmonary 
hypertension.13 Thus it is prudent intraoperatively to avoid 
conditions that will worsen pulmonary hypertension such as 
acidosis, hypoxia and hypercarbia. Ventilatory strategies will 
need to be tailored to the patient’s underlying respiratory 
pathology.
A full blood count should be done preoperatively. There is no 
standardised haemoglobin for surgery, but a baseline level of 
10 g/dl or above is generally recommended.2,14 Patents with low 
haemoglobin should be transfused preoperatively.11 
Leucodepleted blood is generally used to reduce the risk of 
alloimunisation.8,11 Blood-conserving strategies should be 
considered in high-risk procedures, due to a low tolerance for 
bleeding.14 Blood salvage is controversial due to increased risk of 
haemolysis, but has been used safely with low suction pressures 
and leucocyte depletion filters.1,14 There are no standardised 
anaesthesia guidelines for intraoperative blood transfusion 
triggers for patients with beta thalassaemia. However, taking 
into account the recommended baseline trigger of 10  g/dl, it 
would be reasonable to continue this recommendation 
intraoperatively. Due to increased incidence of blood-borne 
infections in these patients, caution must be exercised by staff in 
exposure to the patient’s blood.11
Iron chelation therapy should be optimised with the patient’s 
attending physician.2 Both complications of iron overload and 
adverse effects of iron chelation therapy need to be borne in 
mind.3,7 Iron studies are usually routinely monitored in these 
patients, although MRI studies tend to give a more accurate 
reflection of target organ damage.7
The coagulation profile will need to be checked due to the 
hypercoaguable milieu. However, normal results do not exclude 
a potential for thrombosis. Thus measures still need to be taken 
perioperatively to reduce this risk, for example: compression 
stockings; low molecular heparin; mobilisation.13 The risk of 
thromboembolism is increased in: beta thalassaemia intermedia; 
post-splenectomy; advancing age; transfusion independence; 
personal or family history of thromboembolic events.13
Due to possible renal damage, electrolytes should be checked 
preoperatively and corrected as required, preoperative renal 
function assessed, and renal-protective measures taken as 
appropriate.15 Liver function tests should also be assessed 
preoperatively.3 To minimise further injury, hepatotoxic 
medications should be avoided.3 Endocrine abnormalities 
should be looked for preoperatively and optimised accordingly.3 
Glucose tolerance tests or thyroid function tests may be 
indicated, guided by clinical assessment.2
These patents are immunosuppressed, thus aseptic vigilance 
must be maintained at all times. Prior to a splenectomy, 
pneumococcal, meningococcal and H influenza type B 
immunisations are recommended.16 Appropriate antibiotic 
prophylaxis should be administered.6 In these patients, there is 
an increased risk of poor wound healing postoperatively.10
Both general anaesthesia and neuroaxial techniques have been 
reported as being used safely.9 The technique used must be 
tailored according to the patient and surgery involved. 
Osteopenia and micro-fractures necessitate careful transfers and 
positioning.9 Skin ulcerations if found should be noted, and 
careful padding is required.9 Additional factors to note are 
Table 2: Adverse organ effects of iron overload4,7,9,18
Organ system Clinical feature
Cardiac Cardiac hypertrophy, chamber enlargement, cardiomyopathy, subpericardial deposits leading to myocar-
ditis and pericarditis
Endocrine Endocrinopathies (particularly diabetes mellitus, hypogonadism, hypoparathyroidism, hypothyroidism) 
caused by iron toxicity in the anterior pituitary gland, pancreas and thyroid
Hepatic Fibrosis leading to cirrhosis, liver failure, and increased risk of hepatocellular carcinoma
Renal Nephrotoxicity compounded by anaemia, rapid correction of iron overload, and nephrotoxic iron chelat-
ing agents
Tubular dysfunction with hyperfiltration and reduced concentrating ability leading to: proteinuria; ami-
noaciduria; increased excretion of calcium, magnesium, and phosphate
Glomerular dysfunction with increased glomerular filtration and creatine clearance
Immune system Immunosuppression
Increased risk of bacterial infections, especially Yersinia and Klebsiella species
Respiratory Lung fibrosis with or without interstitial oedema leading to restrictive lung disease (compounded by 
thoracic cage skeletal abnormalities)
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potentially difficult intravenous access, sizing of monitors due to 
small stature, and effect of severe anaemia on pulse oximetry 
readings.17 No specific anaesthesia agents are dictated, but 
rather the choice of agents to be used will be decided by the 
patient’s clinical condition and the surgery planned. These 
patients are at high risk for difficult airway management due to 
facial skeletal deformities.1,11 If a neuroaxial technique is to be 
done, skeletal deformities, pre-existing neurological deficits and 
a hypercoaguable profile must all be taken into consideration.9
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